Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793094 | 1.00 | SLC7A5 (0.57) | SLC7A5PTPN1ALPIPKMPTGS1 | |
| SCHEMBL837931 | 0.86 | SLC7A5 (0.64) | SLC7A5PTPN1ALPIPKMPTGS1 | |
| SCHEMBL31177372 | 0.85 | TRPM8 (0.48) | SLC7A5TRPM8EPHX1 | |
| SCHEMBL26995232 | 0.84 | EPHX1 (0.47) | SLC7A5TRPM8EPHX1 | |
| SCHEMBL26985826 | 0.84 | EPHX1 (0.47) | SLC7A5TRPM8EPHX1 | |
| SCHEMBL2930111 | 0.83 | SLC7A5 (0.51) | SLC7A5PTPN1ALPIPKMPTGS1 | |
| SCHEMBL1802026 | 0.82 | PTPN1 (0.78) | SLC7A5PTPN1ALPIPKMPTGS1 | |
| SCHEMBL18256435 | 0.82 | PTPN1 (0.78) | SLC7A5PTPN1ALPIPKMPTGS1 | |
| SCHEMBL1802025 | 0.82 | PTPN1 (0.78) | SLC7A5PTPN1ALPIPKMPTGS1 | |
| SCHEMBL6831079 | 0.81 | PPARG (0.60) | SLC7A5PTPN1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2616448-B1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| EP-2616448-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-07-24 | — | — | EP | disclosed |
| CN-103119027-A | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER IP GMBH | 2013-05-22 | — | — | CN | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2012035075-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | WO | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | SLC7A5 50/4885PTPN1 4207/4885ALPI 4058/4885 |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | AADAC, NAT1, DNPEP | SLC7A5 2232/4885PTPN1 2189/4885ALPI 1405/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | SLC7A5 39/4885PTPN1 4124/4885ALPI 4126/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | SLC7A5 54/4885PTPN1 4188/4885ALPI 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.